BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15694385)

  • 1. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells.
    Zhang P; Gao W; Li H; Reed E; Chen F
    Biochem Biophys Res Commun; 2005 Mar; 328(2):567-72. PubMed ID: 15694385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
    Liang X; Reed E; Yu JJ
    Int J Mol Med; 2006 May; 17(5):703-8. PubMed ID: 16596250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.
    Zhang P; Wang J; Gao W; Yuan BZ; Rogers J; Reed E
    Mol Cancer; 2004 May; 3():14. PubMed ID: 15125777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
    Bahassi el M; Myer DL; McKenney RJ; Hennigan RF; Stambrook PJ
    Mutat Res; 2006 Apr; 596(1-2):166-76. PubMed ID: 16481012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.
    Cai Z; Chehab NH; Pavletich NP
    Mol Cell; 2009 Sep; 35(6):818-29. PubMed ID: 19782031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.
    Zuco V; Benedetti V; Zunino F
    Cancer Lett; 2010 Jun; 292(2):186-96. PubMed ID: 20042274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
    Wang HC; Chou WC; Shieh SY; Shen CY
    Cancer Res; 2006 Feb; 66(3):1391-400. PubMed ID: 16452194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner.
    Gibson SL; Bindra RS; Glazer PM
    Cancer Res; 2005 Dec; 65(23):10734-41. PubMed ID: 16322218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
    Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
    Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
    Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
    Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHK2-dependent phosphorylation of BRCA1 in hypoxia.
    Gibson SL; Bindra RS; Glazer PM
    Radiat Res; 2006 Oct; 166(4):646-51. PubMed ID: 17007555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR.
    Théard D; Coisy M; Ducommun B; Concannon P; Darbon JM
    Biochem Biophys Res Commun; 2001 Dec; 289(5):1199-204. PubMed ID: 11741320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated checkpoint kinase 2 provides a survival signal for tumor cells.
    Ghosh JC; Dohi T; Raskett CM; Kowalik TF; Altieri DC
    Cancer Res; 2006 Dec; 66(24):11576-9. PubMed ID: 17178848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the intramolecular phosphorylation sites in human Chk2.
    Olsen BB; Larsen MR; Boldyreff B; Niefind K; Issinger OG
    Mutat Res; 2008 Nov; 646(1-2):50-9. PubMed ID: 18812180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1997 Oct; 57(20):4488-92. PubMed ID: 9377558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.